Showing 2271-2280 of 5644 results for "".
- Celanese Announces a Research Agreement with Johns Hopkins University to Advance Sustained Ocular Drug Delivery to the Suprachoroidal Spacehttps://modernod.com/news/celanese-announces-a-research-agreement-with-johns-hopkins-university-to-advance-sustained-ocular-drug-delivery-to-the-suprachoroidal-space/2481417/Specialty materials and chemical company Celanese announced an agreement with Johns Hopkins University Department of Ophthalmology to collaborate on a study of sustained drug delivery to the suprachoroidal space in the eye. A bioinert implant based on the Celanese's VitalD
- Eyenovia Announces Development Collaboration with Formosa Pharmaceuticalshttps://modernod.com/news/eyenovia-announces-development-collaboration-with-formosa-pharmaceuticals/2481412/Eyenovia announced that the company has entered into a development collaboration agreement with Taiwan-based Formosa Pharmaceuticals that seeks to combine Eyenovia’s Optejet dispensing technology with Formosa’s APNT nanoparticle formulation platform for the potential develop
- Bausch + Lomb Launches Social Media Campaign Designed to Raise Awareness of AMDhttps://modernod.com/news/bausch-lomb-launches-social-media-campaign-designed-to-raise-awareness-of-amd/2481393/Bausch + Lomb announced a new social media campaign designed to raise awareness of age-related macular degeneration (AMD). The campaign, "What Sight Inspires You," will feature personal stories and sights from Bausch + Lomb’s SightMatters community, an online educat
- SpyGlass Pharma Unveils 6-Month Data from the First-In-Human Trial of its Drug Delivery Platform for Chronic Eye Conditionshttps://modernod.com/news/spyglass-pharma-unveils-6-month-data-from-the-first-in-human-trial-of-its-drug-delivery-platform-for-chronic-eye-conditions/2481385/SpyGlass Pharma released 6-month data from a first-in-human glaucoma treatment trial showing that its drug delivery platform continues to demonstrate significant IOP lowering in patients with glaucoma or ocular hypertension, according to a company news release. The data were showcased d
- Eyenuk Secures the First European Union MDR Certification for Autonomous AI Detection of DR, AMD, and Glaucomahttps://modernod.com/news/eyenuk-secures-the-first-european-union-mdr-certification-for-autonomous-ai-detection-of-diabetic-retinopathy-amd-and-glaucoma/2481377/Eyenuk has been approved to market its EyeArt AI eye screening system in the European Union for the new uses of detecting age-related macular degeneration (AMD) and glaucomatous optic nerve damage. The EyeArt AI system (version 3.0) has been granted a new European Commiss
- Research Challenges “Sugar Hypothesis” of Diabetic Cataract Developmenthttps://modernod.com/news/research-challenges-sugar-hypothesis-of-diabetic-cataract-development/2481371/New findings from investigators at Brigham and Women’s Hospital, a founding member of the Mass General Brigham health care system, contradict previous notions about sugar’s role i
- Trefoil Therapeutics Announces First Patient Dosed in Phase 1 Study of TTHX1114 for Treatment of Corneal Epithelial Defectshttps://modernod.com/news/trefoil-therapeutics-announces-first-patient-dosed-in-phase-1-study-of-tthx1114-for-treatment-of-corneal-epithelial-defects/2481356/Trefoil Therapeutics announced dosing of the first patient in its phase 1 safety study evaluating TTHX1114 as a topical eye drop formulation designed to reduce the duration and impact of corneal epithelial defects. The phase 1 study is designed to assess t
- Study: Zebrafish Model Helps Explain Eye Developmenthttps://modernod.com/news/study-zebrafish-model-helps-explain-eye-development/2481352/Scientists at the National Eye Institute (NEI) have developed a zebrafish model of NEDBEH—a rare genetic disorder that can cause coloboma, where parts of the eye are missing due to developmental defects. The model provides a new tool for understanding the eye's embryonic developmen
- Pixium Vision Announces Publications Demonstrating the Potential of the Next Generation PRIMA Implanthttps://modernod.com/news/pixium-vision-announces-publications-demonstrating-the-potential-of-the-next-generation-prima-implant/2481348/Pixium Vision announced that the second generation of implants for its bionic vision system PRIMA for atrophic age-related macular degeneration (AMD) could restore vision at five times higher resolution than the current PRIMA implants, according to a company news release. Pixi
- Amber Ophthalmics Announces Positive Topline Phase 2 Data Evaluating Nexagon for the Treatment of Persistent Corneal Epithelial Defect (PCED)https://modernod.com/news/amber-ophthalmics-announces-positive-topline-phase-2-data-evaluating-nexagon-for-the-treatment-of-persistent-corneal-epithelial-defect-pced/2481332/Amber Ophthalmics announced positive topline results from the phase 2 randomized, double-masked, vehicle-controlled clinical trial (EXPEDE) evaluating two topically administered concentrations of Nexagon (lufepirsen ophthalmic gel) for the treatment of persistent corneal epithelial defect (P